The '893 COM patent expires March 2010 and is under re-examination. The '995 COM patent for the atorvastatin enantiomer expires June 2011, but is under review with the USPTO, awaiting re-issuance. Failing to resolve this patent would result in the March 2010 patent expiration. The rest of atorvastatin patents for formulation, crystal structure, and method-of-use expire in 2013-2017.
Quiz: Since PFE’s Lipitor settlement is with Ranbaxy only, why is PFE not concerned that some other company will launch a generic Lipitor when the ‘893 patent expires in Mar 2010?
Market Data 
Markets 
AI
